Immunotherapy for anaplastic thyroid carcinoma: the present and future.
Immunotherapy for anaplastic thyroid carcinoma: the present and future.
复制标题
DOI：
10.3724/zdxbyxb-2021-0273
复制
发表时间：
2021-12-25
影响因子：
--
通讯作者：
Ge, Minghua
中科院分区：
文献类型：
--
作者：
Lu, Xixuan;Bao, Lisha;Ge, Minghua
甲状腺间变性癌（ATC）是内分泌系统最恶性的肿瘤，是一个亟待解决的医学问题。目前针对ATC的免疫治疗研究主要包括切断肿瘤相关巨噬细胞（tumor-associated macrophage， TAM）的募集、诱导TAM重编程并恢复其吞噬功能、靶向T细胞和自然杀伤细胞的相关免疫检查点、基于溶瘤病毒和树突状细胞的肿瘤疫苗、过继免疫治疗等。其中，以免疫检查点靶向阻断程序性死亡-1/程序性死亡配体-1为代表的免疫治疗策略已被初步证实对ATC患者有益，尤其是分子靶向抑制剂与免疫治疗的联合治疗已显示出优异的治疗效果。由于ATC具有很大的异质性，通过开展包括生物、免疫和细胞治疗在内的多种免疫治疗研究，探索下一代免疫检查点抑制剂的治疗潜力，有望为ATC患者提供更多的治疗策略。本文就ATC的潜在免疫治疗靶点及免疫治疗进展进行综述。
Anaplastic thyroid carcinoma (ATC) is the most malignant tumor of endocrine system, which is an urgent medical problem to be solved. At present, immunotherapy studies on ATC mainly include cutting off the recruitment of tumor-associated macrophage (TAM), inducing the reprogramming of TAM and restoring its phagocytic function, targeting related immune checkpoints on T cells and natural killer cells, tumor vaccines based on oncolytic viruses and dendritic cells, and adoptive immunotherapy. Among them, immunotherapy strategies represented by targeted blocking of programmed death-1/programmed death ligand-1 at immune checkpoint have been preliminarily confirmed to benefit ATC patients, especially the combination of molecular targeted inhibitors and immunotherapy has shown excellent therapeutic effects. Due to the great heterogeneity of ATC, it is expected to provide more therapeutic strategies for patients of ATC by carrying out various immunotherapy studies including biological, immune and cellular therapies and exploring the therapeutic potential of the next generation of immune checkpoint inhibitors. This article reviews the potential immunotherapeutic targets of ATC and the progress of immunotherapy.